Narinder Pal Bhalla - 24 Sep 2026 Form 4 Insider Report for Lexeo Therapeutics, Inc. (LXEO)

Reporting relationship: Chief Medical Officer
Issuer ticker: LXEO
Reported as of: 24 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 Sep 2026, 17:15:10 UTC
Prior SEC filing: 01 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/ Youjin Choi, Attorney-in-Fact

Key filing fact

Narinder Pal Bhalla filed Form 4 for Lexeo Therapeutics, Inc. (LXEO) on 28 Sep 2026.

Key facts

This page summarizes Narinder Pal Bhalla's Form 4 filing for Lexeo Therapeutics, Inc. (LXEO).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 28 Sep 2026, 17:15.

Change

Previous filing in this sequence was filed on 01 Jul 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002109299 Primary reporting owner

Bhalla Narinder Pal

Relationship: Chief Medical Officer
Address: C/O LEXEO THERAPEUTICS, INC., 345 PARK AVENUE SOUTH, 6TH FLOOR, NEW YORK
Signature: /s/ Youjin Choi, Attorney-in-Fact
Signature date: 28 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LXEO transaction

Common Stock

Award

Transaction value
Shares: +2,714
Change %: +3.3%
Price: $3.58^*
Shares after: 84,908
Date: 14 Sep 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LXEO transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +54,750
Change %
Price: $0.000000^*
Shares after: 54,750
Date: 24 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 54,750
Exercise price: $3.39
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Lexeo Therapeutics, Inc. 2023 Employee Stock Purchase Plan. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d).

Footnote F2

Includes 49,500 Restricted Stock Units.

Footnote F3

25% of the shares underlying the option vest and become exercisable on September 24, 2027, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.